2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - 260-262
Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Clinical Trials, Study Population, Human
PAPER

823 From rescue to consolidation: Anti-BCMA CAR-T is feasible, highly effective and safe across the AL amyloidosis continuum

Eyal Lebel, Nathalie Asherie, PhD2, Shlomit Kfir-Erenfeld, PhD3, Batia Avni, MD4, Sigal Grisariu, MD5, Shlomo Elias6, Eran Zimran, MD7, Robert Michalshvili8, Vladimir Vaistein9, Shlomzion Aumann10, Miri Assayag11, Marina Krizhevskaya12, Elena Karger13, Marjorie Pick14, Yael C. Cohen, MD15, Irit Avivi Mazza, MD16, Cyrille Cohen17, Polina Stepensky18, Moshe Gatt, MD19
1 Hadassah Medical Center, Jerusalem, Israel, the Hebrew University of Jerusalem, Jerusalem, Israel
2 Hadassah Medical Center, Jerusalem, Israel, the Hebrew University of Jerusalem, Jerusalem, Israel
3 Hadassah Medical Center, Jerusalem, Israel, the Hebrew University of Jerusalem, Jerusalem, Israel
4 Hadassah Medical Center, Jerusalem, Israel, the Hebrew University of Jerusalem, Jerusalem, Israel
5 Hadassah Medical Center, Jerusalem, Israel, the Hebrew University of Jerusalem, Jerusalem, Israel
6 Hadassah Medical Center, Jerusalem, Israel, the Hebrew University of Jerusalem, Jerusalem, Israel
7 Hadassah Medical Center, Jerusalem, Israel, the Hebrew University of Jerusalem, Jerusalem, Israel
8 Hadassah Medical Center, Jerusalem, Israel, the Hebrew University of Jerusalem, Jerusalem, Israel
9 Hadassah Medical Center, Jerusalem, Israel, the Hebrew University of Jerusalem, Jerusalem, Israel
10 Hadassah Medical Center, Jerusalem, Israel, the Hebrew University of Jerusalem, Jerusalem, Israel
11 Hadassah Medical Center, Jerusalem, Israel, the Hebrew University of Jerusalem, Jerusalem, Israel
12 Hadassah Medical Center, Jerusalem, Israel
13 Hadassah Medical Center, Jerusalem, Israel
14 Hadassah Medical Center, Jerusalem, Israel, the Hebrew University of Jerusalem, Jerusalem, Israel
15 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Sourasky Tel Aviv Medical Center, Tel Aviv, Israel
16 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Sourasky Tel Aviv Medical Center, Tel Aviv, Israel
17 Laboratory of Tumor Immunology and Immunotherapy, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel, Ramat Gan, Israel
18 Hadassah Medical Center, Jerusalem, Israel, the Hebrew University of Jerusalem, Jerusalem, Israel
19 Hadassah Medical Center, Jerusalem, Israel, the Hebrew University of Jerusalem, Jerusalem, Israel

Introduction: Rapid, deep suppression of amyloidogenic light chains is critical for organ recovery and survival in light-chain (AL) amyloidosis. We previously reported deep hematologic and organ responses within the phase 1 study with the anti-BCMA CAR-T-cell therapy HBI0101 in relapsed/refractory (R/R) AL. Here we report the long-term outcomes of patients treated in the completed phase 1 study together with patients enrolled in the ongoing phase 2 study, which included patients with R/R AL earlier in the disease course and a cohort of insufficiently responding patients to frontline therapy.

Results: The median age was 64 years (53–82); cardiac and renal involvement were each present in 20/30 (67%) patients, and Mayo stage 3a/3b in 8/30 (27%). R/R patients had received a median of four prior lines (range, 2–10), whereas patients treated for insufficient frontline response had received a single regimen.

Deep hematologic responses were achieved across the treatment continuum. For the entire cohort, the overall response rate  was 29/30 (97%), with complete response (CR)/VGPR achieved in 28/30 (93%), dFLC<1 mg/L in 26/30 (87%), and MRD negativity (10^-5) in 24/27 evaluable patients (89%). Organ responses occurred in 18/25 evaluable patients (72%; cardiac -11/15, renal- 9/14), increasing to 81% among patients achieving a dFLC<1 mg/L. Median times to first hematologic, best hematologic, and first organ response were 6, 13, and 60 days, respectively. After a median follow-up of 22.3 months, median overall survival (OS), progression-free survival (PFS) and duration of response were not reached; estimated 18-month OS and PFS were 63% and 59%, respectively. Of note, four of eight deaths occurred in patients with ongoing deep response but pre-existing severe heart disease.

The insufficient-response to frontline therapy cohort (n=9; median follow-up 4.8 months, too short for survival landmarks) achieved uniformly deep responses: CR/VGPR and dFLC<1 mg/L were achieved in all patients (9/9), and MRD negativity in all evaluable patients (7/7). Organ responses occurred in 7/8 evaluable patients (88%), with median times to first hematologic and organ response of 6 and 47 days, respectively. One patient died from an unrelated second primary malignancy while in ongoing VGPR.

Among the 21 R/R patients (16 patients in the phase 1 study and 5 in the phase 2 study, median follow-up 26.0 months), CR/VGPR was achieved in 19/21 (90%), dFLC<1 mg/L in 17/21 (81%), and organ response in 11/17 evaluable patients (65%). Three of seven deaths occurred despite ongoing remission.

Safety (N=30): CRS occurred in 28/30 (93%), including grade 1–2 in 23 patients and grade 3 in five; there were no grade 4/5 events and no ICANS. Grade ≥3 infections occurred in 8/30 patients. Target organ deterioration among patients with corresponding organ involvement included heart failure exacerbation in 3/20 (15%), acute kidney injury in 4/20 (20%), and liver enzyme elevation in 2/7 (29%). All of which were transient and reversible with supportive care. There were no treatment-related deaths.

Conclusions: Anti-BCMA CAR-T-cell therapy produced rapid, deep and durable hematologic responses across the AL amyloidosis treatment continuum, with near-universal dFLC normalization and high rates of MRD negativity translating into frequent and rapid initial organ responses, particularly among patients achieving dFLC<1 mg/L. Importantly, half of all deaths occurred despite sustained hematologic remission, suggesting that once substantial organ damage has accumulated, hematologic response alone may not prevent mortality. All patients in the non-sufficient response cohort achieved rapidly a CR/VGPR with a dFLC of <1mg/L, and subsequently almost all achieved an organ response, albeit the very short median follow-up. Together, these findings provide a strong rationale for moving CAR-T earlier in the disease course, and supporting further evaluation of CAR-T as an early consolidation/response-deepening strategy in frontline therapy.

Moshe Gatt, MD: No relevant conflicts of interest to declare.